pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Reimbursement status of new drugs approved in 2007-2018 (Source: Translated from Korea Institute of Health and Social Affairs, Future Prospect of Pharmaceuticals and Medium to Long-Term Strategy of Health Policy and Governance, 2019)

Approvedyear Reimbursement starting year Sum (%) Not reimbursed Total

’07 ’08 ’09 ’10 ’11 ’12 ’13 ’14 ’15 ’16 ’17 ’18 ’19
’07 13 9 12 2 1 3 1 2 1 1 1 46 (75.4) 15 61
’08 9 6 7 2 1 25 (58.1) 18 43
’09 3 9 2 1 4 19 (67.9) 9 28
’10 10 13 6 1 4 3 37 (77.1) 11 48
’11 5 11 9 3 2 1 2 33 (64.7) 18 51
’12 6 9 4 4 1 2 26 (68.4) 12 38
’13 6 13 4 4 1 28 (71.8) 11 39
’14 7 25 4 11 2 49 (75.4) 16 65
’15 18 16 15 6 55 (77.5) 16 71
’16 2 22 1 25(46.3) 29 54
’17 9 10 6 25 (56.8) 19 44
’18 9 6 15 (53.6) 13 28

Sum 13 18 21 28 21 29 27 30 55 33 64 31 13 383 (67.2) 187 570
Korean J Clin Pharm 2021;31:1-11 https://doi.org/10.24304/kjcp.2021.31.1.1
© 2021 Korean J Clin Pharm